Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies

OBJECTIVE: Depressive symptoms are common in schizophrenia and can worsen outcomes and increase suicide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar I disorder. This post ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasrallah, Henry A., Cucchiaro, Josephine B., Mao, Yongcai, Pikalov, Andrei A., Loebel, Antony D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411643/
https://www.ncbi.nlm.nih.gov/pubmed/24955752
http://dx.doi.org/10.1017/S1092852914000285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411643/
https://www.ncbi.nlm.nih.gov/pubmed/24955752
http://dx.doi.org/10.1017/S1092852914000285

Ejemplares similares